Inhibitors of HIV-1 entry and integration: Recent developments and impact on treatment

Anil K. Sharma, Varghese George, Ranjini Valiathan, Sudheesh Pilakka-Kanthikeel, Suresh Pallikkuth

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Advances in the drug development against HIV-1 have lead to the identification of new compounds which could be used to target cellular entry and nuclear integration of virus in addition to drugs that commonly target reverse transcriptase and protease. These additional targets have added a new dimension to fight against HIV. Cellular entry of HIV is a multistep procedure involving a range of cellular and molecular interactions between virus envelope protein and receptors expressed on the surface of the target cells, thus providing many opportunities to block infection. Some of these entry inhibitors are currently being used in the clinic and more compounds are under various stages of development. Integration of the HIV-1 DNA is required and essential to maintain the viral DNA in the infected cell. The design and discovery of integrase inhibitors were first focused at targeting the catalytic site of integrase that selectively acting on strand transfer and thus inhibits integration of virus DNA with host cell genome. Thus, entry and integrase inhibitors present a real added value in combined treatment against HIV infection. This review discusses the recent development in the discovery of inhibitors of HIV entry and integration along with some of recent patents in the field.

Original languageEnglish (US)
Pages (from-to)151-161
Number of pages11
JournalRecent Patents on Inflammation and Allergy Drug Discovery
Volume7
Issue number2
DOIs
StatePublished - 2013

Fingerprint

HIV Fusion Inhibitors
Integrase Inhibitors
Virus Integration
HIV-1
HIV
Viral Envelope Proteins
Integrases
DNA Viruses
Patents
RNA-Directed DNA Polymerase
Viral DNA
Pharmaceutical Preparations
HIV Infections
Catalytic Domain
Peptide Hydrolases
Genome
DNA
Infection

Keywords

  • Art
  • Entry inhibitors
  • HIV
  • HIV patents
  • HIV treatment
  • HIV-1
  • Integrase inhibitors
  • Raltegravir

ASJC Scopus subject areas

  • Drug Discovery
  • Immunology and Allergy

Cite this

Inhibitors of HIV-1 entry and integration : Recent developments and impact on treatment. / Sharma, Anil K.; George, Varghese; Valiathan, Ranjini; Pilakka-Kanthikeel, Sudheesh; Pallikkuth, Suresh.

In: Recent Patents on Inflammation and Allergy Drug Discovery, Vol. 7, No. 2, 2013, p. 151-161.

Research output: Contribution to journalArticle

Sharma, Anil K. ; George, Varghese ; Valiathan, Ranjini ; Pilakka-Kanthikeel, Sudheesh ; Pallikkuth, Suresh. / Inhibitors of HIV-1 entry and integration : Recent developments and impact on treatment. In: Recent Patents on Inflammation and Allergy Drug Discovery. 2013 ; Vol. 7, No. 2. pp. 151-161.
@article{3d38939beadb43bd8fcbee3bc2c8e10f,
title = "Inhibitors of HIV-1 entry and integration: Recent developments and impact on treatment",
abstract = "Advances in the drug development against HIV-1 have lead to the identification of new compounds which could be used to target cellular entry and nuclear integration of virus in addition to drugs that commonly target reverse transcriptase and protease. These additional targets have added a new dimension to fight against HIV. Cellular entry of HIV is a multistep procedure involving a range of cellular and molecular interactions between virus envelope protein and receptors expressed on the surface of the target cells, thus providing many opportunities to block infection. Some of these entry inhibitors are currently being used in the clinic and more compounds are under various stages of development. Integration of the HIV-1 DNA is required and essential to maintain the viral DNA in the infected cell. The design and discovery of integrase inhibitors were first focused at targeting the catalytic site of integrase that selectively acting on strand transfer and thus inhibits integration of virus DNA with host cell genome. Thus, entry and integrase inhibitors present a real added value in combined treatment against HIV infection. This review discusses the recent development in the discovery of inhibitors of HIV entry and integration along with some of recent patents in the field.",
keywords = "Art, Entry inhibitors, HIV, HIV patents, HIV treatment, HIV-1, Integrase inhibitors, Raltegravir",
author = "Sharma, {Anil K.} and Varghese George and Ranjini Valiathan and Sudheesh Pilakka-Kanthikeel and Suresh Pallikkuth",
year = "2013",
doi = "10.2174/1872213X11307020006",
language = "English (US)",
volume = "7",
pages = "151--161",
journal = "Recent Patents on Inflammation and Allergy Drug Discovery",
issn = "1872-213X",
publisher = "Bentham Science Publishers B.V.",
number = "2",

}

TY - JOUR

T1 - Inhibitors of HIV-1 entry and integration

T2 - Recent developments and impact on treatment

AU - Sharma, Anil K.

AU - George, Varghese

AU - Valiathan, Ranjini

AU - Pilakka-Kanthikeel, Sudheesh

AU - Pallikkuth, Suresh

PY - 2013

Y1 - 2013

N2 - Advances in the drug development against HIV-1 have lead to the identification of new compounds which could be used to target cellular entry and nuclear integration of virus in addition to drugs that commonly target reverse transcriptase and protease. These additional targets have added a new dimension to fight against HIV. Cellular entry of HIV is a multistep procedure involving a range of cellular and molecular interactions between virus envelope protein and receptors expressed on the surface of the target cells, thus providing many opportunities to block infection. Some of these entry inhibitors are currently being used in the clinic and more compounds are under various stages of development. Integration of the HIV-1 DNA is required and essential to maintain the viral DNA in the infected cell. The design and discovery of integrase inhibitors were first focused at targeting the catalytic site of integrase that selectively acting on strand transfer and thus inhibits integration of virus DNA with host cell genome. Thus, entry and integrase inhibitors present a real added value in combined treatment against HIV infection. This review discusses the recent development in the discovery of inhibitors of HIV entry and integration along with some of recent patents in the field.

AB - Advances in the drug development against HIV-1 have lead to the identification of new compounds which could be used to target cellular entry and nuclear integration of virus in addition to drugs that commonly target reverse transcriptase and protease. These additional targets have added a new dimension to fight against HIV. Cellular entry of HIV is a multistep procedure involving a range of cellular and molecular interactions between virus envelope protein and receptors expressed on the surface of the target cells, thus providing many opportunities to block infection. Some of these entry inhibitors are currently being used in the clinic and more compounds are under various stages of development. Integration of the HIV-1 DNA is required and essential to maintain the viral DNA in the infected cell. The design and discovery of integrase inhibitors were first focused at targeting the catalytic site of integrase that selectively acting on strand transfer and thus inhibits integration of virus DNA with host cell genome. Thus, entry and integrase inhibitors present a real added value in combined treatment against HIV infection. This review discusses the recent development in the discovery of inhibitors of HIV entry and integration along with some of recent patents in the field.

KW - Art

KW - Entry inhibitors

KW - HIV

KW - HIV patents

KW - HIV treatment

KW - HIV-1

KW - Integrase inhibitors

KW - Raltegravir

UR - http://www.scopus.com/inward/record.url?scp=84878656477&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878656477&partnerID=8YFLogxK

U2 - 10.2174/1872213X11307020006

DO - 10.2174/1872213X11307020006

M3 - Article

C2 - 23578097

AN - SCOPUS:84878656477

VL - 7

SP - 151

EP - 161

JO - Recent Patents on Inflammation and Allergy Drug Discovery

JF - Recent Patents on Inflammation and Allergy Drug Discovery

SN - 1872-213X

IS - 2

ER -